» Articles » PMID: 38566430

Discovering Genetic Biomarkers for Targeted Cancer Therapeutics with EXplainable Artificial Intelligence

Overview
Publisher Wiley
Specialty Oncology
Date 2024 Apr 3
PMID 38566430
Authors
Affiliations
Soon will be listed here.
References
1.
Millstein J, Budden T, Goode E, Anglesio M, Talhouk A, Intermaggio M . Prognostic gene expression signature for high-grade serous ovarian cancer. Ann Oncol. 2020; 31(9):1240-1250. PMC: 7484370. DOI: 10.1016/j.annonc.2020.05.019. View

2.
Bowtell D, Bohm S, Ahmed A, Aspuria P, Bast Jr R, Beral V . Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015; 15(11):668-79. PMC: 4892184. DOI: 10.1038/nrc4019. View

3.
Aghayev T, Mazitova A, Fang J, Peshkova I, Rausch M, Hung M . IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma. Cancer Discov. 2022; 12(8):1960-1983. PMC: 9357073. DOI: 10.1158/2159-8290.CD-20-1628. View

4.
Garsed D, Pandey A, Fereday S, Kennedy C, Takahashi K, Alsop K . The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. Nat Genet. 2022; 54(12):1853-1864. PMC: 10478425. DOI: 10.1038/s41588-022-01230-9. View

5.
Shmatko A, Laleh N, Gerstung M, Kather J . Artificial intelligence in histopathology: enhancing cancer research and clinical oncology. Nat Cancer. 2022; 3(9):1026-1038. DOI: 10.1038/s43018-022-00436-4. View